Clinical Trials
44 trialsTesting Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
University of California, Irvine
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
FIT-001
Kura Oncology, Inc.
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
University of Arizona
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
CAMILLA
University of Pittsburgh
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
CheckMate040
Bristol-Myers Squibb
COSMIC-312
Exelixis
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
CAPIO
National Health Research Institutes, Taiwan
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
ACTION
Fundacion Clinic per a la Recerca Biomédica
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
CaPture
University of Leipzig
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CPAB
Chulalongkorn University
CABOTEM
National Cancer Institute, Naples
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
ABACO
University of Campania Luigi Vanvitelli
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
University of Washington
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver
Ph II CABOGIST in GIST
European Organisation for Research and Treatment of Cancer - EORTC
CELESTIAL
Exelixis
CaboMAb
Duke University
CaboCHILD
Johannes Gutenberg University Mainz
Immunocabo
Istituto Clinico Humanitas
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Massachusetts General Hospital